# Laekna Therapeutics' Oral Amylin Agonist LAE124 Selected for Poster at Obesity Week 2026

> Laekna Therapeutics will present animal data on LAE124, its oral dual amylin/calcitonin receptor agonist for obesity.

- Published: 2026-11-12T04:45:39+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-12/laekna-lae124-obesity-week-poster
- Source: [PR Newswire](https://www.prnewswire.com/news-releases/obesity-week-2026--laekna-announces-poster-presentation-on-lae124-an-internally-discovered-oral-small-molecule-amylin-receptor-agonist-302937235.html)

## Key takeaways

- LAE124, Laekna Therapeutics' internally discovered oral small-molecule dual Amylin/Calcitonin receptor agonist, was selected for a poster presentation at Obesity Week 2026.
- In DIO rats, daily oral dosing of LAE124 for 28 days produced a dose-dependent reduction in body weight, and a single dose reduced acute food intake.
- LAE124 is in IND-enabling studies, and Laekna Therapeutics is also developing ActRII candidates LAE102, LAE103 and LAE123.

Laekna Therapeutics said on November 11, 2026 that LAE124, its internally discovered oral small-molecule dual Amylin/Calcitonin receptor agonist for obesity, has been selected for a poster presentation at the 44th Annual Meeting of The Obesity Society, held with Obesity Week 2026. The [PR Newswire](https://www.prnewswire.com/news-releases/obesity-week-2026--laekna-announces-poster-presentation-on-lae124-an-internally-discovered-oral-small-molecule-amylin-receptor-agonist-302937235.html) announcement places the compound in IND-enabling studies.

## Where LAE124 Fits in Laekna's Pipeline

[Laekna Therapeutics](https://akta.pro/company-profiles/0000z8p/laekna-therapeutics) is a clinical-stage biotechnology company developing novel therapeutics for obesity, cancer and liver fibrosis through internally discovered drug candidates, with licensing partnerships including Eli Lilly and Qilu Pharma. The company said LAE124 will be presented in the "Emerging Weight-Loss Therapies & Long-Term Outcomes" session on November 15, as poster number 465, at the Gaylord National Resort & Convention Center in Washington, D.C. Obesity Week 2026 runs from November 14 to 17.

In animal studies, the company said, LAE124 produced a significant dose-dependent reduction in acute food intake after a single dose in DIO rats, and daily oral dosing for 28 days led to a robust dose-dependent reduction in body weight. The compound showed low clearance, high oral bioavailability and a long half-life in animals, with a predicted profile supporting once-daily oral dosing in humans at a low dose. Dr. Justin GU, Chief Scientific Officer of Laekna, said: "Orally available small molecule DACRA will be highly competitive in the obesity market due to improved dosing convenience and enhanced patient adherence."

## Laekna's Obesity and Metabolic Portfolio

According to akta.pro [company records](https://akta.pro/company-data), Laekna Therapeutics was founded in 2016 and is headquartered in Shanghai, with cash and bank balances of RMB 743.8 million as of June 30, 2025. The same records list more than 20 projects in its pipeline as of its 2025 ESG report and a clinical collaboration with Eli Lilly and Company, signed in November 2024, to accelerate global development of LAE102, an ActRIIA monoclonal antibody for obesity treatment. Laekna retains global rights for LAE102.

## Earlier Steps Toward the Poster

In August 2026, Laekna announced that its new drug application for LAE002, an AKT inhibitor for treating HR+/HER2- breast cancer, had been accepted by China's National Medical Products Administration, Investing.com reported. In June 2026, BioWorld reported that Laekna is licensing ex-China rights to its PI3Kα pan-mutant selective inhibitor LAE-118 to U.S.-based Vasque Bio Inc. in a deal worth up to $527 million.

## What Comes Next for LAE124

The poster presentation is scheduled for November 15, 2026, from 2:30 pm to 3:30 pm EST. The company said it plans to continue developing LAE124 and other metabolic therapies, and that it is accelerating development of therapies targeting novel pathways such as Amylin and UCN2.

## Companies in this story

- [Laekna Therapeutics company profile](https://akta.pro/company-profiles/0000z8p/laekna-therapeutics) · website: https://www.laekna.com

---
News for Agent · https://newsforagent.com/llms.txt